title: Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients.
abstract: BACKGROUND
  To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC.
  
  
  METHODS
  The expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells.
  
  
  RESULTS
  The status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery.
  
  
  CONCLUSIONS
  SATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.
authors: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, People's Republic of China.
authors: Tian-Run
authors: TR
authors: Liu
authors: Li-Hua
authors: LH
authors: Xu
authors: An-Kui
authors: AK
authors: Yang
authors: Qian
authors: Q
authors: Zhong
authors: Ming
authors: M
authors: Song
authors: Man-Zhi
authors: MZ
authors: Li
authors: Li-Juan
authors: LJ
authors: Hu
authors: Fu-Jin
authors: FJ
authors: Chen
authors: Ze-Dong
authors: ZD
authors: Hu
authors: Ping
authors: P
authors: Han
authors: Mu-Sheng
authors: MS
authors: Zeng
mesh_terms: D000368:Aged; D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000473:pathology; D036961:Matrix Attachment Region Binding Proteins / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016019:Survival Analysis; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D036961:Matrix Attachment Region Binding Proteins; D012333:RNA, Messenger; C521297:SATB2 protein, human; D014157:Transcription Factors